

FOR IMMEDIATE RELEASE

AMNEAL LAUNCHES FELBAMATE ORAL SUSPENSION

Latest first-to-market generic expands antiepileptics family

Bridgewater, NJ (USA), December 21, 2011 – Amneal Pharmaceuticals, LLC is pleased to announce availability of the first generic Felbamate oral suspension in 600 mg/5 mL strength. Amneal's newest first-to-market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic Felbatol® (a registered trademark of Meda Pharmaceuticals Inc.). Annual U.S. sales of Felbatol® are \$17.6 million according to June 2011 IMS Health market data. Amneal received ANDA approval for Felbamate oral suspension from the U.S. FDA on December 16, 2011.

The Amneal generic is available in two sizes, 8 fl oz/240 mL and 16 fl oz/473 mL. The pink, bubble gum-flavored liquid does not require refrigeration and is manufactured in Amneal's fully cGMP-compliant Branchburg, NJ plant. Felbamate oral suspension is shipping and available through wholesalers-distributors as well as directly to the trade.

"This approval further expands our liquids portfolio and complements our tablet-form of Felbamate, which launched in September," said Chirag Patel, Amneal's president. "Additionally, by bringing another first-to-market generic to the public, we are reinforcing our commitment to provide pharmacy customers and the consumer with high-quality, affordable pharmaceuticals," continued Patel.

Amneal Pharmaceuticals, LLC, with principal offices in Bridgewater, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as "Generic's New Generation," the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Efficient ANDA approvals and diverse product acquisitions are key to Amneal's aggressive growth strategy, as is the company's strong commitment to deep customer relationships and maximum value creation. Amneal delivers high-quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.

###

CONTACT:

Jim Luce
Executive Vice President, Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
620 Newport Center Drive, 14th Floor
Newport Beach, California 92660